Contact
Please use this form to send email to PR contact of this press release:
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
TO:
Please use this form to send email to PR contact of this press release:
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
TO: